HER2 Positive Breast Cancer Market is driven by Targeted Therapies
The HER2‑Positive breast cancer market centers on diagnostic tools and therapeutic agents that target the human epidermal growth factor receptor 2 (HER2), overexpressed in roughly 20% of breast cancer cases. Key products include monoclonal antibodies (trastuzumab, pertuzumab), antibody‑drug conjugates (ado‑trastuzumab emtansine, fam‑trastuzumab deruxtecan), and emerging biosimilars. These...
0 Commentaires 0 Parts 319 Vue 0 Aperçu